AVG Announces Results of Its Annual General Meeting of Shareholders
Get Alerts AVG Hot Sheet
Join SI Premium – FREE
AMSTERDAM, June 12, 2015 /PRNewswire/ -- AVG Technologies N.V. (NYSE: AVG) today announced that it held its annual general meeting of shareholders on Thursday, June 11, 2015. Jan Haars, serving as independent supervisory director of AVG's supervisory board and first appointed in August 2011, and Jonathan Meeks, serving as a non-independent supervisory director of AVG's supervisory board and first appointed in October 2009, were re-appointed by the general meeting of shareholders as supervisory directors of AVG's supervisory board for a period of four (4) years ending immediately following the AGM 2019.
About AVG Technologies (NYSE: AVG)
AVG is the online security company providing leading software and services to secure devices, data and people. AVG's award-winning technology is delivered to over 200 million monthly active users worldwide. AVG's Consumer portfolio includes internet security, performance optimization, and personal privacy and identity protection for mobile devices and desktops. The AVG Business portfolio - delivered by managed service providers, VARs and resellers - offers IT administration, control and reporting, integrated security, and mobile device management that simplify and protect businesses.
All trademarks are the property of their respective owners.
Keep in touch with AVG
http://www.twitter.com/AVGfreehttp://www.facebook.com/AVG https://www.linkedin.com/company/28199 http://blogs.avg.com/ http://www.youtube.com/user/officialAVG
Logo - http://photos.prnewswire.com/prnh/20120306/SF65434LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/avg-announces-results-of-its-annual-general-meeting-of-shareholders-300098396.html
SOURCE AVG Technologies N.V.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mega Matrix to consolidate shares 20-to-1 to maintain NYSE listing
- MEDIPAL HOLDINGS CORPORATION and JCR Pharmaceuticals Dose First Patient in Global Phase I/II Trial of JR-446 for Mucopolysaccharidosis Type IIIB
- $83 Million Sale of Two Oregon Multifamily Assets Brokered by Institutional Property Advisors
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share